Expanded Access Program for Mezigdomide (in combination with Carfilzomib/dex or Bortezomib/dex) For Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- Sponsor:
- Bristol Myers Squibb
- Sponsor Study ID:
- CA057-1070
- CTO #:
- 104362
- NCT Number:
- NCT06994117
- Phase:
- N/A
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Multiple Myeloma
- Study Objectives:
- This is an expanded access designed to provide access to Mezigdomide for eligible participants
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Dominick, Anthony, at dominica@musc.edu
- Study Coordinator, Blankenship, Abigail, at blankeab@musc.edu
Trial opened at the following institutions:
Medical University of South Carolina